Is pressurized intraperitoneal aerosol chemotherapy safe and effective in the treatment of peritoneal metastases from pancreatic adenocarcinoma?

<p id="docs-internal-guid-41f3440d-7fff-87cd-c879-90d1250ec304" style="line-height: 1.7999999999999998; margin-top: 12pt; margin-bottom: 12pt;" dir="ltr"><span style="font-size: 12pt; font-family: 'Times New Roman'; color: #000000; background-col...

Full description

Saved in:
Bibliographic Details
Main Authors: Krzysztof Smoluchowski (Author), Michał Sekuła (Author), Blanka Świerczyńska (Author), Adrian Undziakiewicz (Author), Magdalena Suchodolska (Author)
Format: Book
Published: Kazimierz Wielki University, 2020-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2eeef3d5a9e547c8a6f401def77bd9a5
042 |a dc 
100 1 0 |a Krzysztof Smoluchowski  |e author 
700 1 0 |a Michał Sekuła  |e author 
700 1 0 |a Blanka Świerczyńska  |e author 
700 1 0 |a Adrian Undziakiewicz  |e author 
700 1 0 |a Magdalena Suchodolska  |e author 
245 0 0 |a Is pressurized intraperitoneal aerosol chemotherapy safe and effective in the treatment of peritoneal metastases from pancreatic adenocarcinoma? 
260 |b Kazimierz Wielki University,   |c 2020-09-01T00:00:00Z. 
500 |a 2391-8306 
500 |a 10.12775/JEHS.2020.10.09.053 
520 |a <p id="docs-internal-guid-41f3440d-7fff-87cd-c879-90d1250ec304" style="line-height: 1.7999999999999998; margin-top: 12pt; margin-bottom: 12pt;" dir="ltr"><span style="font-size: 12pt; font-family: 'Times New Roman'; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Introduction and purpose:</span><span style="font-size: 12pt; font-family: 'Times New Roman'; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> Pancreatic adenocarcinoma (PAC) is the third most common cancer of the gastrointestinal tract in the Western population. Peritoneal metastases (PM) affect 5-10% patients with PAC at the moment of diagnosis and 50% of patients who experience a recurrence after a successful resection. This review aims to evaluate the efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of PM from PAC based on the literature available on PubMed website</span></p><p style="line-height: 1.7999999999999998; margin-top: 12pt; margin-bottom: 12pt;" dir="ltr"><span style="font-size: 12pt; font-family: 'Times New Roman'; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Brief description of the state of knowledge:</span><span style="font-size: 12pt; font-family: 'Times New Roman'; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> PIPAC is a relatively new method of treatment and the number of studies investigating its application in the treatment of PM from PAC is scarce. Nevertheless, initial findings suggest that PIPAC is linked to 15,6 months of the median overall survival, while standard intravenous chemotherapy reaches only 7,6 months . Furthermore, PIPAC seems to be a fairly safe method, as no grade 3 or grade 4 complications (according to CTCAE v4.0) occurred. However, all of the studies involved an unrepresentative number of patients and they were not free from a selection bias. Moreover, due to the novelty of the PIPAC procedure, it still needs to be properly standardised. </span></p><p style="line-height: 1.7999999999999998; margin-top: 0pt; margin-bottom: 10pt;" dir="ltr"><span style="font-size: 12pt; font-family: 'Times New Roman'; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Conclusions: </span><span style="font-size: 12pt; font-family: 'Times New Roman'; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Available data concerning the application of PIPAC in the treatment of PM from PDAC is limited. Large prospective studies consisting of control groups are still lacking. Nevertheless, the results of accessible studies displaying a median OS of participants reaching 14-16,8 months, with no G3 and G4 complications, are encouraging and justify further research.</span></p> 
546 |a EN 
546 |a ES 
546 |a PL 
546 |a RU 
546 |a UK 
690 |a aerosol chemotherapy 
690 |a pancreatic adenocarcinoma 
690 |a peritoneal metastases 
690 |a pipac 
690 |a Education 
690 |a L 
690 |a Sports 
690 |a GV557-1198.995 
690 |a Medicine 
690 |a R 
655 7 |a article  |2 local 
786 0 |n Journal of Education, Health and Sport, Vol 10, Iss 9, Pp 445-454 (2020) 
787 0 |n https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/31358 
787 0 |n https://doaj.org/toc/2391-8306 
856 4 1 |u https://doaj.org/article/2eeef3d5a9e547c8a6f401def77bd9a5  |z Connect to this object online.